by Coco Jervis The neglected crisis of childhood tuberculosis (TB) is finally garnering some long-overdue attention. TAG hosted Forgotten But Not Gone: Childhood TB, a federal advocacy dialogue and strategy session in Washington, D.C. this January. We brought together over…
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
In recognition of World Tuberculosis day on March 24th, Treatment Action Group (TAG) calls for the re-focusing of attention on the tremendous burden that tuberculosis (TB) plays around the world. TB is a disease of the poor – more than 80% of TB cases worldwide arise in the global south. According to the World Health Organization, nearly 4,000 people die every day because of TB.
March 2012 – When it comes to drug-resistant tuberculosis (DR-TB), the global community is failing to “get it right.” Millions of people around the world suffer from this dangerous, yet treatable, infectious disease. Yet, in over a decade, less than…
On January 5, 2012, TAG held a Childhood TB Federal Advocacy Meeting in Washington, D.C. The meeting was cosponsored by STOP TB, RESULTS/ACTION, the Center for Global Health Policy, and the American Thoracic Society (ATS). Some of the highlights of the…
By Richard Jefferys, with the assistance of Claire Wingfield, Eleonora Jimenez and Javid Syed. 7/1/2011 - The relatively small community of researchers, policymakers and advocates involved in the search for an effective TB vaccine met in Tallinn, Estonia in September,…
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
TB Alliance's REMox TB program leverages ACTG sites to advance testing of improved TB treatments November 15, 2011, Durban, South Africa— The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID)…
New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005.